SCHEMBL25403147

SCHEMBL25403147

Fc1cc(F)cc(Nc2ccc3[nH]c(CSc4ccnc(C(F)(F)F)c4)nc3c2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 2/20 0.36
▸ NPC1 O15118 4/20 0.36
▸ RAB9A P51151 4/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ABCB1 P08183 6/20 0.35
▸ IDH2 P48735 1/20 0.34
▸ ENPP1 P22413 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TYMS P04818 2/20 0.33
▸ NTRK1 P04629 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30039536 1.00 PDE10A (0.36) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL26260643 0.93 ABCB1 (0.40) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL30041878 0.92 ABCB1 (0.43) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL26260641 0.92 ABCB1 (0.43) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL30040820 0.91 ENPP1 (0.36) PDE10AABCB1ENPP1LMNA
SCHEMBL26260715 0.91 ENPP1 (0.36) PDE10AABCB1ENPP1LMNA
SCHEMBL26260681 0.91 GRM4 (0.35) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL30040660 0.90 TRPA1 (0.40) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL25398632 0.90 TRPA1 (0.40) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2
SCHEMBL25401982 0.90 ENPP1 (0.37) PDE10ANPC1RAB9ASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4085054-B1 NEW PQSR INVERSE AGONISTS HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2025-02-19 — — EP disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed
US-20230286942-A1 NEW PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2023-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286942-A1 NEW PqsR INVERSE AGONISTS QRFPR, P2RY11, GPR55 PDE10A 356/4885NPC1 4374/4885RAB9A 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback